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Letters to the Editoractual ethical standard procedures
to meet corresponding concerns.
Tavlasoglu and colleagues particu-
larly pointed out in the valve-in-
native-ring case that preoperative
echocardiography should have deter-
mined the severe calcification and
thus allowed optimized surgical plan-
ning to include the valve replacement
technique in a severely calcified mitral
annulus, as previously presented by
Mihaljevic and associates.2 In this
particular case, we must recognize
that the preoperative findings concern-
ing mitral annular calcifications were
obviously underestimated, resulting
in the attempt at conventional mitral
repair. At any rate, this apparent misin-
terpretation cannot be argued and thus
was intentionally not included in our
recently published series.1 Despite
extraordinary diligence, however, real
life sometimes includes painful twists
of fate. The pivotal point was when
our operating surgeon came into this
futile situation and a bail-out plan
was needed. Too much crossclamp
time had been spent to allow further
extension, and death on the operating
table was no option. For those reasons
we performed as an absolute bail-out
procedure the direct-view implanta-
tion of the transcatheter valve.1 As
Tavlasoglu and colleagues correctly
remarked, this resulted in progressive
paravalvular leakage and the begin-
ning of valve dislocation on the first
postoperative day. Only after second-
look surgery, including refixation of
the transcatheter valve with a single
running suture to an atrial cuff, was a
stable valvular function achieved.
We absolutely agree with the con-
cerns stated by Tavlasoglu and col-
leagues. For those reasons, we have
already pointed out that ‘‘this case
demonstrated that ‘valve-in-native
ring’ procedures are not really feasible’’
and this bail-out procedure potentially
only ‘‘worked once, but can surely not
be recommended at all.’’1 We summa-
rized that ‘‘with the present available de-
vices, ‘valve-in-native-ring’ seems not
to be. possible.’’1 With regard toThe Journalongoing developments, valve-in-native-
ring could become feasible in the future,
but at the present, it is surely not.3
From our point of view, conven-
tional surgery unarguably remains
the standard treatment for nearly any
mitral valve disease. Nonetheless, we
believe, that valve-in-valve and
valve-in-ring procedures in the mitral
position have a particular value in
selected cases. In this spirit, we like
to cite Michael Mack’s sophisticated
commentary on valve-in-valve proce-
dures: ‘‘The procedure is extremely
promising, but as with any new tech-
nology or technique, embrace should
be cautious until the limitations have
been well defined and addressed.’’4
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COMPAREDWITH MITRALof Thoracic and Cardiovascular SurgerVALVE REPAIR IN
CONCOMITANTAORTIC AND
MITRALVALVE SURGERY?
To the Editor:
The article by Coutinho and col-
leagues1 draws attention to a classic
topic that has not been deeply investi-
gated, whether to replace or repair the
mitral valve in double-valve surgery.
We congratulate them for keeping
our knowledge up to date on this issue.
The efforts toward defining the exact
solution have great importance. In
this regard, we would like to make
some contributions and discuss the
subject.
It is a fact that although the reported
freedoms from endocarditis (P ¼
.002) and major valve-related adverse
events (P ¼ .0026) were better for the
mitral valve repair group, the expected
concomitant improved survival1 was
not seen. We think that the answer
should be sought in the structural dif-
ferences of the left ventricles when
considering etiologic classification of
both groups. The mitral valve repair
group mainly consisted of patients
with three etiologies (functional [n ¼
91; 43.5%], degenerative [n ¼ 44;
21.1%], and rheumatic [n ¼ 58;
27.8%], whereas the mitral replace-
ment group mainly consisted of
patients with rheumatic etiology
(n ¼ 40; 76.9%). When New York
Heart Association functional classifi-
cation was compared between the
two groups, statistically significant
differences were detected (P ¼ .015);
however the pathophysiologic changes
in the left ventricles resulting in New
York Heart Association functional
class III and IV were also different be-
tween the groups. It is well known that
left ventricular function is well pre-
served in rheumatic mitral valve
disease relative to degenerative or
functional mitral valve disease. The
primary pathologic condition in mitral
valve stenosis is that the increased left
atrial pressure is reflected on the pul-
monary bed, whereas the primary
pathologic condition in degenerativey c Volume 147, Number 6 1993
Letters to the Editoror functional mitral valve disease is
decreased cardiac output, which is
compensated for by left ventricular
dilatation. Both mechanisms are
responsible for the symptoms. This
approach was confirmed by Coutinho
and colleagues1 (left atrial diameter,
52.3  8.7 vs 60.6  9.4 mm; P<
.0001; left ventricular end-diastolic
dimension, 65.8  9.6 vs 58.5  8.3
mm; P< .0001; left ventricular end-
systolic dimension, 46.1  9.3 vs
37.8  8.3 mm; P<.0001; and mean
pulmonary arterial systolic pressure,
53.1  16.7 vs 60.9  17.1 mm Hg;
P ¼ .004). In addition, the pre-
served left ventricular functions were
demonstrated in the mitral replace-
ment group (shortening fraction
30.2%  8.0% vs 35.5%  8.5%;
P<.000).1
When degenerative and functional
mitral valve disease subgroups were
compared between the mitral valve
repair and mitral replacement groups
in terms of cumulative patient sur-
vival, a statistically significant differ-
ence would have been detected. This
situation was shown by Coutinho and
colleagues1 in their Figure 1, C. In a
prospective study including patients
with degenerative etiology, a better
positive remodeling was observed by
Pandis and coworkers2 in their
repair group versus their replacement
group.2 A retrospective study
including 439 patients by Athanaso-
poulos and associates3 indicated that
when mitral regurgitation remained
untreated surgically until left ventric-
ular diameter were moderately to
severely abnormal or the left atrium
was moderately or severely dilated,
successful reverse remodeling became
less likely.
In conclusion, we speculate that
had major valve-related adverse
events been neglected, better survival
would have been observed in the
mitral replacement group because of
better preserved left ventricular func-
tions and dimensions. Likewise, if
inadequate left ventricular reverse re-
modeling were neglected, better1994 The Journal of Thoracic andsurvival would have been observed
in the mitral valve repair group.
Finally, adding major valve-related
adverse events and inadequate left
ventricular reverse remodeling to the
calculation equalized the overall sur-
vival between the two groups.
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We thank Tavlasoglu and co-
workers for the contribution of their
letter to the interesting discussion
about the decision to replace or repair
the mitral valve in double valve sur-
gery (aortic and mitral). Despite the
existence of a significant number of
reports in the literature dealing with
concomitant aortic and mitral valve
surgery, few have directly addressed
this question. Some would argue that
if the aortic valve needs replacementCardiovascular Surgery c June 2014with a prosthesis, an additional mitral
prosthesis should not alter the
outcome significantly.
One landmark study that ap-
proached this subject in a methodical
way for the first time was published
by the Cleveland Clinic group1; how-
ever, there were differences between
their study population and our own,2
namely the prevalence of rheumatic
disease, which would cause one to
expect different results. In the Cleve-
land Clinic study, 70% of the mitral
valves had rheumatic involvement,
whereas nearly two-thirds of our pa-
tients had secondary (functional) or
degenerative mitral disease. Our pop-
ulation is more consistent with the
current daily practice in Western
countries, because rheumatic etiology
is declining. Furthermore, secondary
(nonischemic and non–dilated cardio-
myopathy) mitral regurgitation in the
context of aortic valve disease is gain-
ing importance,3 because patients are
increasingly older, and moderate or
moderate-to-severe mitral regurgita-
tion is frequently found. It is thus
important to know the outcome (sur-
vival and event-free survival) after
repair or replacement of the mitral
valve.
One major limitation of our study
was the heterogeneity of the popula-
tion; the groups (repair vs replace-
ment) were very different with
regard to important variables. Natu-
rally, the decision to repair or to
replace was influenced by the charac-
teristics of the patient and of the valve,
and a repair was preferred whenever
possible, which may have created a
bias. This was the rationale for per-
forming propensity score matching
to obtain more similar groups for com-
parison, a well-known and accepted
statistical method for this type of anal-
ysis. Relevant demographic, patient,
and echocardiographic characteris-
tics, including mitral valve pathology,
were included in the propensity score
analysis.
We could not demonstrate a clear
survival benefit in the repair group,
